Blood Cancer United secures remaining luveltamab tazevibulin supply to support compassionate use for children with a rare AML.
- In the news
Pharmaceutical Economics and Policy
Moving in Cancer Discovery.
- Moved, week to 23 Oct 2026
- 1
- Papers in 60 days
- 6
Add Pharmaceutical Economics and Policy as an interest in JClubFree on iPhone and Android · interests shape Home, Discover and your digest
Rebuilt
Moved this week
Latest in Pharmaceutical Economics and Policy
Newest first · last 60 days
Formulary rejections of single-source branded drugs increased by 67.4% from 2018 to 2024, leading to delayed or absent treatment in over half of initial rejection cases.
- Open access
Add Pharmaceutical Economics and Policy as an interest in JClub
Browse JClub
Journals this month
- bioRxiv6131
- medRxiv1703
- PNAS447
- Sci Adv354
- JAMA262
- Environ Res230
- BMJ182
- Environ Pollution165
- Nat Commun161
- Science141
- Nature138
- Lancet128
- Cell Rep120
- NEJM119
- mBio107
- Plant Cell Environ107
- Curr Biol106
- J Exp Bot106
Topics moving, week to 23 Oct 2026
- Single-cell and spatial transcriptomics6
- Neuroinflammation and Neurodegeneration Mechanisms5
- Bacteriophages and microbial interactions5
- Gut microbiota and health5
- Genomics and Phylogenetic Studies4
- Cancer Genomics and Diagnostics4
- Cancer Immunotherapy and Biomarkers4
- Alzheimer's disease research and treatments3
- Inflammatory Bowel Disease3
- Influenza Virus Research Studies3